[go: up one dir, main page]

WO2006061430A3 - Itgbl-1 utile comme cible regulant la metastase osseuse et le developpement osseux - Google Patents

Itgbl-1 utile comme cible regulant la metastase osseuse et le developpement osseux Download PDF

Info

Publication number
WO2006061430A3
WO2006061430A3 PCT/EP2005/056636 EP2005056636W WO2006061430A3 WO 2006061430 A3 WO2006061430 A3 WO 2006061430A3 EP 2005056636 W EP2005056636 W EP 2005056636W WO 2006061430 A3 WO2006061430 A3 WO 2006061430A3
Authority
WO
WIPO (PCT)
Prior art keywords
bone
bone metastasis
metastasis
markers
development
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/056636
Other languages
English (en)
Other versions
WO2006061430A2 (fr
Inventor
Philippe Clement-Lacroix
Philippe Clezardin
Amanda Jackson
Philippe Pujuguet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Galapagos SAS
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
ProSkelia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, ProSkelia SAS filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of WO2006061430A2 publication Critical patent/WO2006061430A2/fr
Publication of WO2006061430A3 publication Critical patent/WO2006061430A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur un procédé, et sur des produits de diagnostic des maladies osseuses utilisant des marqueurs de gènes spécifiques de la métastase osseuse tels que ITGBL-1.
PCT/EP2005/056636 2004-12-10 2005-12-09 Itgbl-1 utile comme cible regulant la metastase osseuse et le developpement osseux Ceased WO2006061430A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63459704P 2004-12-10 2004-12-10
US60/634,597 2004-12-10

Publications (2)

Publication Number Publication Date
WO2006061430A2 WO2006061430A2 (fr) 2006-06-15
WO2006061430A3 true WO2006061430A3 (fr) 2006-08-03

Family

ID=36088317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/056636 Ceased WO2006061430A2 (fr) 2004-12-10 2005-12-09 Itgbl-1 utile comme cible regulant la metastase osseuse et le developpement osseux

Country Status (1)

Country Link
WO (1) WO2006061430A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL177006A0 (en) * 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
EP2370091B1 (fr) * 2008-12-05 2017-04-12 Whitehead Institute for Biomedical Research Compositions et procédés concernant le mir-31

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009481A1 (en) * 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
US20040058340A1 (en) * 2001-06-18 2004-03-25 Hongyue Dai Diagnosis and prognosis of breast cancer patients
US20040137489A1 (en) * 2002-12-05 2004-07-15 Shaughnessy John D. Molecular determinants of myeloma bone disease and uses thereof
WO2004063355A2 (fr) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Nouveaux procedes de diagnostic d'un cancer metastatique, compositions et procedes de depister des modulateurs du cancer metastatique
WO2004092410A2 (fr) * 2003-04-15 2004-10-28 Thiesen Hans-Juergen Methode de diagnostic de la polyarthrite rhumatoide ou de l'osteoarthrite

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009481A1 (en) * 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
US20040058340A1 (en) * 2001-06-18 2004-03-25 Hongyue Dai Diagnosis and prognosis of breast cancer patients
US20040137489A1 (en) * 2002-12-05 2004-07-15 Shaughnessy John D. Molecular determinants of myeloma bone disease and uses thereof
WO2004063355A2 (fr) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Nouveaux procedes de diagnostic d'un cancer metastatique, compositions et procedes de depister des modulateurs du cancer metastatique
WO2004092410A2 (fr) * 2003-04-15 2004-10-28 Thiesen Hans-Juergen Methode de diagnostic de la polyarthrite rhumatoide ou de l'osteoarthrite

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERG R W ET AL: "Cloning and Characterization of a Novel beta Integrin-Related cDNA Coding for the Protein TIED (''Ten beta Integrin EGF-like Repeat Domains'') That Maps to Chromosome Band 13q33: A Divergent Stand-Alone Integrin Stalk Structure", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 56, no. 2, 1 March 1999 (1999-03-01), pages 169 - 178, XP004444998, ISSN: 0888-7543 *
ITOH ET AL: "CLONING AND SEQUENCE ANALYSIS OF CDNA ENCODING THE PRECURSOR OF A HUMAN ENDOTHELIUM-DERIVED VASOCONSTRICTOR PEPTIDE, ENDOTHELIN: IDENTITY OF HUMAN AND PORCINE ENDOTHELIN", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 231, no. 2, April 1998 (1998-04-01), pages 440 - 444, XP002936503, ISSN: 0014-5793 *
KANG YIBIN ET AL: "A multigenic program mediating breast cancer metastasis to bone.", CANCER CELL, vol. 3, no. 6, June 2003 (2003-06-01), pages 537 - 549, XP008062522, ISSN: 1535-6108 *
YIN JUAN JUAN ET AL: "A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. 19, 16 September 2003 (2003-09-16), pages 10954 - 10959, XP008062573, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2006061430A2 (fr) 2006-06-15

Similar Documents

Publication Publication Date Title
WO2003093441A3 (fr) Procede de regulation de l'expression genique
WO2006007207A3 (fr) Procedes et dispositifs pour la determination de sequence d'acides nucleiques
WO2007053702A8 (fr) Synthese de nucleotides fluorescents photoclivables a modification 3'-o-allyl en quadrichromie et procedes associes
WO2005107762A3 (fr) Entites, compositions chimiques et procedes
WO2004037988A3 (fr) Methodes de synthese de l'adn complementaire
WO2007149762A3 (fr) Cryptage de données de suivi
WO2009037266A3 (fr) Procédé de détection ou de quantification d'une mutation tronquante
WO2009076676A3 (fr) Compositions et méthodes de production d'isoprène
WO2006020768A3 (fr) Oligonucleotides chimiquement modifies
WO2006085906A3 (fr) Methode de detection directe d'arn de diagnostic
WO2006092213A8 (fr) Pyrazolylcarboxanilides
WO2007056143A3 (fr) Entites et compositions chimiques et methodes associees
WO2007039290A3 (fr) Methodes et acides nucleiques pour l'analyse d'expression genique associee au pronostic de troubles de proliferation cellulaire
WO2006102283A3 (fr) Acides beta-lactamylalcanoiques destines au traitement des troubles premenstruels
WO2004087735A3 (fr) Anticorps proteolytiques et covalents
WO2007056469A3 (fr) Entites et compositions chimiques et methodes associees
WO2006135904A3 (fr) Procede permettant d'obtenir de meilleurs resultats pour des applications qui utilisent directement ou indirectement des resultats de dosage d'expression genetique
WO2007056078A3 (fr) Entites et compositions chimiques et methodes associees
WO2007014197A3 (fr) Vecteurs d'expression de levures pour la production du facteur itf
WO2005074645A3 (fr) Procedes et compositions permettant de moduler l'angiogenese
WO2006078422A3 (fr) Methode de modulation de la croissance tumorale et des metastases
WO2006061430A3 (fr) Itgbl-1 utile comme cible regulant la metastase osseuse et le developpement osseux
WO2006072607A3 (fr) Plantes transplastomiques depourvues du gene marqueur selectionnable
WO2007109609A8 (fr) Procédé permettant d'inhiber l'angiogenèse
WO2006073602A3 (fr) Modulation arni du gene de fusion bcr-abl et applications associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05821759

Country of ref document: EP

Kind code of ref document: A2